| Literature DB >> 25474311 |
Hajime Watanobe1, Tomoyuki Furutani2, Masahiko Nihei3, Yu Sakuma3, Rie Yanai4, Miyuki Takahashi4, Hideo Sato4, Fumihiko Sagawa5.
Abstract
BACKGROUND: A possible increase in thyroid cancer in the young represents the most critical health problem to be considered after the nuclear accident in Fukushima, Japan (March 2011), which is an important lesson from the Chernobyl disaster (April 1986). Although it was reported that childhood thyroid cancer had started to increase 3-5 yr after the Chernobyl accident, we speculate that the actual period of latency might have been shorter than reported, considering the delay in initiating thyroid surveillance in the then Soviet Union and also the lower quality of ultrasonographic testing in the 1980s. Our primary objectives in the present study were to identify any possible thyroid abnormality in young Fukushima citizens at a relatively early timepoint (20-30 months) after the accident, and also to strive to find a possible relationship among thyroid ultrasonographic findings, thyroid-relevant biochemical markers, and iodine-131 ground deposition in the locations of residence where they stayed during very early days after the accident. METHODS ANDEntities:
Mesh:
Substances:
Year: 2014 PMID: 25474311 PMCID: PMC4256387 DOI: 10.1371/journal.pone.0113804
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Estimated 131I ground deposition across Fukushima Prefecture as of March 15th 2011.
FNPP1: Fukushima Daiichi Nuclear Power Plant.
Figure 2Sample sifting processes towards analyses.
Figure 3Individual locations of residence where the final 1,137 subjects stayed during the period of March 15th–31st 2011.
The dots indicate the individual locations of residence. FNPP1: Fukushima Daiichi Nuclear Power Plant.
Comparison of thyroid ultrasonographic findings, serum hormonal data, and urinary iodine concentrations between the two groups with and without prophylactic actions against thyroid exposure to radioiodine after the nuclear accident.
| Number of subjects | Prevalence of nodule | Preva-lence of solid nodule (%) | Preva-lence of cyst (%) | Total number of nodules | Number of solid nodules | Number of cysts | The largest diameter of solid nodule | The largest diameter of cyst | Serum TSH (mIU/L) | Serum fT3 (pmol/L) | Serum fT4 (pmol/L) | Serum Tg (µg/L) | UIC (µg/L) | |
|
| 303 | 74.1 | 4.1 | 72.5 | 2.5±1.6 | 0.06±0.33 | 2.4±1.6 | 5.1±3.1 | 2.5±1.0 | 2.0±1.0 (208) | 6.3±0.7 (208) | 16.5±1.9 (208) | 22.4±21.2 (208) | 294 (414) |
|
| 834 | 72.4 | 4.2 | 70.9 | 2.4±1.7 | 0.05±0.23 | 2.4±1·7 | 5.2±3·0 | 2.6±1.1 | 2.0±1.1 (523) | 6.3±0.8 (523) | 16.4±1.9 (523) | 20.9±12·3 (523) | 262 (377) (538) |
Group I comprises the subjects who took potassium iodide (KI) after the nuclear accident, those who increased seaweed consumption following the accident, and those who did both.
Group II comprises the subjects except Group I.
Percentage of subjects who had solid nodules, cysts, or both.
The sum of the numbers of solid nodules and cysts in each subject.
The number was calculated including the subjects without solid nodule or cyst, who were considered to have a “zero” lesion.
The data were derived from only the subjects who had solid nodules (47 subjects) or cysts (811 subjects).
Serum hormonal data were derived from a total of 731 subjects.
UIC data were derived from a total of 770 subjects.
Mean ± S.D.
Median (IQR).
The numbers in parentheses indicate the number of subjects who contributed to the serum hormonal or UIC data in the respective groups.
Differences between the two groups were analyzed by Chi-square test (for the percentage data), pairwise t-test (for the mean ± S.D. data), or Kruskal-Wallis test [for the median (IQR) data].
There were no statistically significant differences in the thyroid ultrasonographic findings, serum hormonal data, and the UIC between the two groups.
TSH, thyroid-stimulating hormone; fT3, free triiodothyronine; fT4, free thyroxine; Tg, thyroglobulin; UIC, urinary iodine concentration.
Relationship between the thyroid nodularity and the 131I ground deposition in the locations of residence after the nuclear accident.
| Number of lesions | Number of subjects |
131I ground deposition in the locations of residence (Bq/m2) | |
|
| 0 | 308 | 517 (482) |
| 1 | 122 | 525 (539) | |
| 2 | 98 | 578 (552) | |
| 3 | 174 | 630 (513) | |
| 4 or more | 435 | 536 (499) | |
|
| 0 | 1,090 | 532 (498) |
| 1 | 41 | 601 (541) | |
| 2 | 5 | 286 (12,245) | |
| 3 or more | 1 | 578 (0) | |
|
| 0 | 326 | 517 (486) |
| 1 | 121 | 526 (569) | |
| 2 | 85 | 568 (535) | |
| 3 | 174 | 635 (506) | |
| 4 or more | 431 | 535 (500) |
Values of individual subjects were determined based on the data shown in Figure 1.
The sum of the numbers of solid nodules and cysts in each subject.
Median (IQR).
Non-parametric multiple comparison test with Kruskal-Wallis test was employed to analyze whether the 131I ground deposition differed as a function of the total number of nodules and the number of solid nodules or cysts.
Significantly different from the “zero-nodule” group (P = 0.007).
Significantly different from the “zero-cyst” group (P = 0.004).
Figure 4Scatter plot of the largest diameter of solid nodule vs. the 131I ground deposition in the 47 subjects who had solid nodules in the thyroid.
Regression analysis revealed that there was no significant correlation between the two parameters.
Figure 5Scatter plot of the largest diameter of cyst vs. the 131I ground deposition in the 811 subjects who had cysts in the thyroid.
Regression analysis revealed that there was no significant correlation between the two parameters.
Thyroid ultrasonographic findings and thyroid-related hormonal data in the five groups with different ranges of urinary iodine concentrations.
| UIC (µg/L) | ∼49 | 50∼99 | 100∼199 | 200∼299 | 300∼ |
| Number of subjects | 49 | 119 | 248 | 128 | 226 |
| Total number of nodules | 2.5±1.7 | 2.6±1.5 | 2.7±1.5 | 2.6±1.5 | 2.5±1.6 |
| Number of solid nodules | 0.04±0.24 | 0.08±0.42 | 0.05±0.20 | 0.04±0.15 | 0.04±0.23 |
| Number of cysts | 2.5±1.7 | 2.6±1.5 | 2.7±1.5 | 2.6±1.5 | 2.4±1.6 |
| The largest diameter of solid nodule (mm) | 1.5 | 5.8±2.7 | 5.7±3.6 | 3.7±0.7 | 4.9±2.0 |
| The largest diameter of cyst (mm) | 2.6±0.9 | 2.6±1.1 | 2.6±1.1 | 2.4±0.8 | 2.4±1.0 |
| Serum TSH (mIU/L) | 2.3±1.3 (30) | 2.0±1.0 (85) | 1.9±1.2 (177) | 1.9±0.9 (89) | 1.9±1.0 (147) |
| Serum fT3 (pmol/L) | 6.3±1.6 (30) | 6.3±0.8 (85) | 6.3±0.9 (177) | 6.2±0.6 (89) | 6.3±0.6 (147) |
| Serum fT4 (pmol/L) | 15.5±1.3 (30) | 15.5±1.5 (85) | 16.8±2.6 (177) | 16.8±2.1 (89) | 16.6±1.7 (147) |
| Serum Tg (µg/L) | 22.7±10.3 (30) | 24.0±28.2 (85) | 23.8±24.0 (177) | 20.8±11.1 (89) | 22.8±14.1 (147) |
Data are expressed as the mean ± S.D.
The sum of the numbers of solid nodules and cysts in each subject.
The number was calculated including the subjects without solid nodule or cyst, who were considered to have a “zero” lesion.
The data were derived from only the subjects who had solid nodules or cysts.
In this UIC group, only one subject had a solid nodule.
Serum hormonal data were derived from a total of 528 subjects.
The numbers in parentheses indicate the number of subjects who contributed to the serum hormonal data in the respective groups.
Intergroup differences were analyzed by ANOVA, and there were no statistically significant differences in the ultrasonographic indicators and hormonal data among the five groups.
UIC, urinary iodine concentration; TSH, thyroid-stimulating hormone; fT3, free triiodothyronine; fT4, free thyroxine; Tg, thyroglobulin.